Two human hemoglobins designed to inhibit the polymerization of sickle hemoglobin (Hb S; a2os2) have been produced. Mutations that disrupt the ability of Hb S to form polymers were introduced into the normal human 3-globin gene by site-specific mutagenesis. These mutations affect the axial and lateral contacts in the sickle fiber. The recombinant hemoglobin designated anti-sickling hemoglobin 1 (Hb AS1) contains the mutations 1822 glutamic acid to alanine and 1380 asparagine to lysine. Hb AS2 has the same 1822 glutamic acid to alanine mutation combined with p87 threonine to glutamine. Human a-and 13s-globin genes were separately fused downstream of 3-globin locus control region sequences and these constructs were coinjected into fertilized mouse eggs.
affect the axial and lateral contacts in the sickle fiber. The recombinant hemoglobin designated anti-sickling hemoglobin 1 (Hb AS1) contains the mutations 1822 glutamic acid to alanine and 1380 asparagine to lysine. Hb AS2 has the same 1822 glutamic acid to alanine mutation combined with p87 threonine to glutamine. Human a-and 13s-globin genes were separately fused downstream of 3-globin locus control region sequences and these constructs were coinjected into fertilized mouse eggs.
Transgenic mouse lines that synthesize high levels of each anti-sickling hemoglobin were established and anti-sickling hemoglobins were purified from hemolysates and characterized. Both Sickle cell disease results from an A to T transversion in the sixth codon of the human (3-globin gene (1, 2) . This mutation leads to the substitution of a nonpolar valine for a polar glutamic acid residue on the surface of the hemoglobin molecule. At low oxygen tensions, the (6 valine interacts with a natural hydrophobic pocket on the surface of a second hemoglobin tetramer and initiates the polymerization of Hb S into long fibers composed of seven pairs of double strands (3) (4) (5) (6) (7) (8) . The formation of these fibers reduces the flexibility of erythrocytes and leads to the occlusion of small capillaries. Intracellular fiber formation also results in erythrocyte membrane damage and increased cell lysis. The ensuing disease is characterized by a chronic hemolytic anemia with episodes of severe pain and tissue damage that can result in stroke, kidney failure, heart disease, infection, and other complications (9).
The structure of the fiber that forms in sickle erythrocytes was derived from x-ray diffraction studies of Hb S crystals (10) . Hb S tetramers are composed of two a-globin subunits (a2) and two (s-globin subunits ((32) and form characteristic double strands. Interactions along the long axis of the fiber are termed axial contacts, whereas interactions along the sides of tetramers are lateral contacts (Fig. 1A) (9) . The (36 valine plays a critical role in the lateral contact by interacting with the hydrophobic residues (385 phenylalanine and (388 leucine (Fig. 1A) . Hb A (a2(32) has these same hydrophobic residues and is readily incorporated into sickle fibers. An important axial contact is the interaction of the (322 glutamic acid with the imidazole group of the a20 histidine on an adjacent tetramer (11) (Fig. 1A) . The physiologic relevance of specific amino acids in the formation of the Hb S fiber has been demonstrated by experiments in which the polymerization of mixtures of Hb S and mutant hemoglobins was analyzed (12) . These mixing experiments highlighted the particular importance of residues (22 and Genes. Plasmids were constructed by standard procedures (24) . Mutagenesis was performed using the Altered Sites system (Promega) (25) . The mutagenic oligonucleotides were as follows: (22, DNase hypersensitive sites 1-5 (5' HS 1-5) of the P-globin LCR (26) . These constructs were injected into fertilized mouse eggs, and blood from mice that developed was analyzed by IEF to identify transgenic animals that synthesize high levels of human hemoglobin (26, 28) . Transgenic lines were established and hemolysates obtained from several animals were analyzed by anion-exchange HPLC to quantitate the amounts of human, mouse, and hybrid hemoglobins (27) . Fig. 2A and C demonstrate that 28% of total hemoglobin was Hb AS1 in one aI3Asl transgenic line and 18% of total hemoglobin was Hb AS2 in one apAS2 transgenic line. Hemoglobins AS1 and AS2 were isolated by preparative IEF (28) and the purity of the human hemoglobins was assessed by denaturing reverse-phase HPLC, which separates the aand P-globin subunits (29, 30) . Fig. 2 B and D demonstrate that Hb AS1 was e90o pure and Hb AS2 was purified to homogeneity.
Functional Analysi of Recombinant Human Hemoglobins. The OECs for purified Hb AS1 and Hb AS2 are illustrated in Fig. 3 A and C (31) . These sigmoidally shaped curves demonstrate the normal cooperativity ofoxygen binding (Fig.  3 A and C) . The P5o value, which measures the partial pressure of oxygen at which hemoglobin is half-saturated, was determined for Hb AS1 and Hb AS2 and compared with Hb A and Hb F ( Table 1 ). The P50 for Hb AS1 is elevated slightly and this hemoglobin responds normally to the allosteric effector BPG-that is, oxygen affinity is decreased in (Fig. 3B) . The P50 for Hb AS2 is slightly lower than normal (6.7 mmHg) but BPG raises this value to 8.4 mmHg (Fig. 3D) . The oxygen affinity of Hb AS2 is functionally equivalent to Hb F in the presence of 2 mM BPG and, therefore, Hb AS2 should adequately bind and deliver oxygen in vivo. Inhibition of Hb S Polymerization by Recombinant Human Hemoglobins. The ability of hemoglobins AS1 and AS2 to disrupt Hb S polymerization was analyzed by delay time measurements (32) . Briefly, Hb S (100%6) or mixtures of Hb S (75%) and Hb A, AS1, AS2, or F (25%) were deoxygenated, and polymerization as a function of time was measured spectrophotometrically as the temperature of the hemoglobin solution was raised from 0°C to 30°C (32, 33) . Fig. 4A demonstrates that HbS polymerizes relatively rapidly and that Hb A, AS1, AS2, and F delay Hb S polymerization to different extents. Hb AS1 inhibits Hb S polymerization more efficiently than Hb A; however, Hb AS1 inhibits much less effectively than Hb F, which is known to inhibit sickling in vivo at a 3:1 ratio (13-15). Finally, Hb AS2 inhibits Hb S polymerization at approximately the same level as Hb F. This finding strongly suggests that Hb AS2 will inhibit HbS polymerization in vivo if expression of AS2 at a level of 25% of total hemoglobin can be achieved.
The delay times determined in Fig. 4A were all measured at a concentration of 60 mg/dl. 3, which agree well with those shown previously in high phosphate buffer (32) . At higher concentrations of hemoglobin, the delay times for Hb AS2 and Hb F overlap, indicating that Hb AS2 and Hb F have virtually identical antipolymerization activity.
The results described above demonstrate that the genetic modification of two surface amino acids in Hb A produces a unique human hemoglobin (Hb AS2) that inhibits Hb S polymerization as effectively as Hb F. As discussed above, the 3-globin LCR enhances f-globin gene expression much more effectively than y-globin gene expression in adult erythroid cells. Therefore pAS2, which is a 3-globin gene with the antipolymerization properties of y-globin, may be the molecule of choice for future genetic therapy of sickle cell disease. Further modifications of this anti-sickling 3-globin gene may provide a hemoglobin that surpasses Hb F in its ability to disrupt the polymerization of Hb S.
